基于超高效液相色谱-串联质谱法的脓毒症患者血清非靶向脂质组学分析
该前瞻性观察研究于2019年9月至2020年4月在山西白求恩医院ICU纳入30例确诊脓毒症患者,并与30例年龄匹配的健康受试者对照,采用超高效液相色谱-串联质谱法(UPLC-MS/MS)分析血清脂质代谢物。以FC>2.0或FC<0.5、P<0.05及VIP>1筛选出72种差异脂质代谢物,基于MetaboAnalyst 5.0鉴定出24种可区分脂质代谢物,包括8种PE、7种LPC、6种PC、2种LPE和1种PS。与健康志愿者相比,脓毒症患者多数脂质分子表达下调(PC、LPC、LPE及部分PE),部分PE和PS上调,主要与甘油磷脂中的PE(18:0p/20:4)、PC(16:0/16:0)和LPC(18:1)代谢通路相关。作者认为上述三种脂质分子可能是脓毒症预测和干预的新靶点。
要点
- 脓毒症患者与年龄匹配健康人血清脂质组学存在显著差异,共筛选出72种差异脂质代谢物(FC>2.0或FC<0.5,P<0.05,VIP>1)。
- 基于MetaboAnalyst 5.0鉴定出24种可区分脂质代谢物:8种PE、7种LPC、6种PC、2种LPE和1种PS。
- 与健康志愿者相比,脓毒症患者PC、LPC、LPE及部分PE表达下调,部分PE和PS上调。
- 差异主要涉及甘油磷脂中PE(18:0p/20:4)、PC(16:0/16:0)和LPC(18:1)代谢通路。
- 作者认为PE(18:0p/20:4)、PC(16:0/16:0)和LPC(18:1)可能是脓毒症预测和干预的新靶点。
适用人群与场景
- 2019年9月至2020年4月山西白求恩医院ICU收治的30例确诊脓毒症患者,采集晨起上肢浅静脉血。
- 同期30例年龄匹配的健康受试者作为对照。
诊断标准与关键阈值
- 差异脂质代谢物筛选标准:FC>2.0或FC<0.5,P<0.05,VIP>1。
研究设计与关键结果
- 研究类型:前瞻性观察研究;样本量:脓毒症患者30例、年龄匹配健康受试者30例;单中心(山西白求恩医院ICU)。
- 方法:UPLC-MS/MS分析血清脂质代谢物,质控样本经基峰光谱(BPC)分析并验证实验重复性;采用Student t检验和倍数变化(FC)筛选差异脂质代谢物;PCA和OPLS-DA评估模型并筛选VIP差异代谢物;MetaboAnalyst平台数据库分析脂质分子代谢通路。
- 质控结果:BPC结果显示实验重复性良好、实验数据可靠。
- 模型参数:PCA模型主要参数模型解释率R2X=0.511,提示模型可靠;OPLS-DA模型R2Y=0.954、Q2=0.913,提示模型稳定可靠。
- 差异代谢物:以FC>2.0或FC<0.5、P<0.05、VIP>1为条件,共获得72种差异脂质代谢物。
- 基于MetaboAnalyst 5.0鉴定出24种可区分脂质代谢物,包括8种磷脂酰乙醇胺(PE)、7种溶血磷脂酰胆碱(LPC)、6种磷脂酰胆碱(PC)、2种溶血磷脂酰乙醇胺(LPE)和1种磷脂酰丝氨酸(PS)。
- 与健康志愿者相比,脓毒症患者多数脂质分子表达下调,包括PC、LPC、LPE及部分PE;部分PE和PS上调;主要与甘油磷脂中的PE(18:0p/20:4)、PC(16:0/16:0)和LPC(18:1)代谢通路相关。
证据类型、等级与局限
- 证据类型:前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为PE(18:0p/20:4)、PC(16:0/16:0)和LPC(18:1)可能是脓毒症预测和干预的新靶点。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To analyze the changes of serum lipidomics in patients with sepsis and healthy controls, search for the differences of lipid metabolites, and reveal the changes of lipidomics in the process of sepsis.
METHODS: A prospective observational study was conducted. From September 2019 to April 2020, morning blood samples of upper extremity superficial veins were collected from 30 patients with definite sepsis diagnosed in intensive care unit (ICU) of Shanxi Bethune Hospital and 30 age-matched healthy subjects during the same period. Serum lipid metabolites were analyzed by ultra-high performance liquid chromatography-mass spectrometry/mass spectrometry (UPLC-MS/MS), and the quality control samples were analyzed by base peak spectroscopy (BPC) and verified experimental repetition. Student t-test and fold change (FC) were used for screening significant differences in lipid metabolites and determining their expression changes. Principal component analysis (PCA) and orthogonal projectionto latent structure discriminant analysis (OPLS-DA) were used to determine the entire allocation of experimental groups apiece, access the quality of being near to the true value of model, and screen the differential lipid metabolites with variable importance of projection (VIP). Finally, Metabo Analyst platform database was used to analyze lipid molecular metabolic pathways.
RESULTS: BPC results showed that the experimental repeatability was good and the experimental data was reliable. The main parameter model interpretation rate of PCA model R2X = 0.511, indicating that the model was reliable. The main parameter model interpretation rate of OPLS-DA model R2Y = 0.954, Q2 = 0.913, indicating that the model was stable and reliable. With FC > 2.0 or FC < 0.5, P < 0.05, a total of 72 differential lipid metabolites were obtained based on VIP > 1. Based on Metabo Analyst 5.0, 24 distinguishable lipid metabolites were identified including 8 phosphatidylethanolamine (PE), 7 lysophosphatidylcholine (LPC), 6 phosphatidylcholine (PC), 2 lysophosphatidylethanolamine (LPE) and 1 phosphatidylserine (PS). Compared with healthy volunteers, the lipid molecules expression proved down-regulated in most sepsis patients, including PC, LPC, LPE, and some PE, while some PE and PS were up-regulated, which was mainly related to the PE (18:0p/20:4), PC (16:0/16:0) and LPC (18:1) metabolic pathways in glycerophospholipids.
CONCLUSIONS: There are significant differences in lipid metabolites between the sera of sepsis patients and healthy volunteers. PE (18:0p/20:4), PC (16:0/16:0) and LPC (18:1) may be new targets for sepsis prediction and intervention.
参考来源
- Wang S, Liang J, Shi H, et al. [Nontargeted lipidomic analysis of sera from sepsis patients based on ultra-high performance liquid chromatography-mass spectrometry/mass spectrometry]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35692196. doi:10.3760/cma.j.cn121430-20210612-00875
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。